Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New camera could make cancer treatment safer by better tracking radiation

NCT ID NCT04467567

Knowledge-focused Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a new type of camera (VERITON-CT) can accurately measure radiation doses in patients receiving Lutathera, a treatment for certain cancers. Fifteen adults were scanned with both the new camera and a standard camera at different times after treatment. The goal was to see if the new camera could provide reliable dose information with fewer scans, which could make the process easier for patients and doctors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lutathera (lutetium Lu 177 dotatate)
What this could lead to
If successful, this could lead to a simpler, faster way to measure radiation doses during Lutathera treatment, potentially improving patient safety and treatment planning.
What could go wrong
This is a very small, early-stage study (15 people) focused on measurement methods, not treatment outcomes. The new camera may not prove more accurate or practical in routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

15 people

The number who actually took part.

Started

Nov 2020

Finished

Jul 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Major adult subject * ECOG ≤ 2 * Subject receiving treatment with Lutathera® * Subject having given written, free and informed consent * Affiliation to a social security scheme Exclusion Criteria: * Contraindication to treatment with Lutathera® * Subject referred to in articles L. 1121-5, L. 1121-7 and L1121-8 of the public health code. * Pregnant woman, parturient or nursing mother. * Subject with a legal protection measure (guardianship, curatorship, safeguard of justice). * Subject unable to express consent. * Subject deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care under Articles L. 3212-1 and L.3213-1

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dosimetry are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dosimetry

Contacts and locations

Locations

  • Chru Nancy

    Vandœuvre-lès-Nancy, 54511, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.